Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the 2014 American Academy of Ophthalmology Scientific Meeting
October 07, 2014 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Oct. 7, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that additional positive anatomic and visual...
Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the Retina Society 47th Annual Scientific Meeting
September 09, 2014 09:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Sept. 9, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that data from the IMPACT study, a phase II...
Ohr Pharmaceutical Announces Additional Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Wet-AMD; The IMPACT Study
August 13, 2014 08:30 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Aug. 13, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced additional interim data from the Phase II study...
Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion
August 11, 2014 09:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced data supporting the use of Squalamine Eye Drops...
Ohr Pharmaceutical to Present at the 2014 Wedbush Life Sciences Management Access Conference
August 08, 2014 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Aug. 8, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Sam Backenroth, Chief Financial Officer, will...
Ohr Pharmaceutical Announces Upcoming Squalamine Eye Drop Clinical Data Presentations at the 2014 Annual Meeting of the American Society of Retina Specialists
August 07, 2014 09:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Aug. 7, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that data from clinical studies evaluating...
Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc. (NASDAQ: OHRP); Raises Price Target to $31
June 26, 2014 09:00 ET
|
Vista Partners LLC
SAN FRANCISCO, CA--(Marketwired - Jun 26, 2014) - Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (NASDAQ: OHRP) ("The Company" or "OHR") and raised its...
Ohr Pharmaceutical Announces Positive Interim Top-Line Clinical Results From Phase II Study of Squalamine Eye Drops in Patients With Wet AMD
June 24, 2014 07:00 ET
|
Ohr Pharmaceutical, Inc.
Patients treated with Squalamine eye drops plus Lucentis® PRN demonstrated a 65 percent additional relative benefit in visual acuity versus placebo eye drops plus Lucentis PRN
Percentage...
Ohr Pharmaceutical to Host Conference Call and Webcast to Discuss Squalamine Interim Phase II Data in Wet-AMD
June 23, 2014 16:30 ET
|
Ohr Pharmaceutical, Inc.
Webcast to be Held on Tuesday, June 24 at 8:30am Eastern
Webcast & Slides Available at www.OhrPharmaceutical.com
NEW YORK, June 23, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc....
Vista Partners Publishes June 2014 Macroeconomic & Investment Newsletter
June 03, 2014 09:00 ET
|
Vista Partners LLC
SAN FRANCISCO, CA--(Marketwired - Jun 3, 2014) - Vista Partners ("Vista") published its FREE Macroeconomic & Investment Monthly Newsletter for the month of June. Each monthly newsletter from...